A multi-center, open labeled phase I/IIa study to evaluate safety, tolerability and efficacy of a therapeutic hepatitis B vaccine in oral antiviral drug-treated chronic hepatitis B virus carriers
Phase of Trial: Phase I/II
Latest Information Update: 15 Nov 2017
At a glance
- Drugs CVI HBV-002 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- 06 Nov 2017 Planned number of patients changed from 36 to 56.
- 06 Nov 2017 Status changed from recruiting to completed.
- 04 Mar 2016 New trial record